- Home
- PED vs ANL Comparison
PED vs ANL Comparison
Compare PED & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PED | ANL |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 293.4M |
| IPO Year | 2012 | 2022 |
Fundamental Metrics
Financial Performance| Metric | PED | ANL |
|---|---|---|
| Price | $16.01 | $7.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $30.00 | $16.00 |
| AVG Volume (30 Days) | ★ 827.2K | 210.3K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $39,553,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 28.49 | N/A |
| 52 Week Low | $0.43 | $0.88 |
| 52 Week High | $18.89 | $12.09 |
Technical Indicators
Market Signals| Indicator | PED | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 88.65 | 46.82 |
| Support Level | $0.54 | $7.21 |
| Resistance Level | N/A | $9.98 |
| Average True Range (ATR) | 0.47 | 1.07 |
| MACD | 1.64 | -0.31 |
| Stochastic Oscillator | 85.71 | 24.49 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.